MRNS 外匯新聞
Marinus Pharma Says Phase 3 Trial Of IV Ganaxolone In RSE Meets First Co-primary Endpoint
Pharmaceutical company Marinus Pharmaceuticals, Inc. (MRNS) announced Monday topline results from the Phase 3 double-blind, randomized, placebo-controlled RAISE trial evaluating the safety and efficacy of intravenous (IV) ganaxolone for the treatment of refractory status epilepticus (RSE).
RTTNews
|
142天前
